Clinical Trial: A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07107490) titled 'A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER' on July 30.

Brief Summary: This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Extensive Stage Small Cell Lung Cancer

Intervention: DRUG: ALPS12

ALPS12 as an IV infusion

DRUG: obinutuzumab

Obinutuzumab as an IV infusion

Recruitmen...